Biomarkers for Prostate Cancer: From Diagnosis to Treatment
-
Published:2023-10-31
Issue:21
Volume:13
Page:3350
-
ISSN:2075-4418
-
Container-title:Diagnostics
-
language:en
-
Short-container-title:Diagnostics
Author:
Chen Jia-Yan1, Wang Pei-Yan2ORCID, Liu Ming-Zhu3, Lyu Feng1, Ma Ming-Wei1, Ren Xue-Ying1, Gao Xian-Shu1ORCID
Affiliation:
1. Department of Radiation Oncology, Peking University First Hospital, Beijing 100034, China 2. School of Information, University of Michigan, Ann Arbor, MI 48109, USA 3. Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fuzhou 350014, China
Abstract
Prostate cancer (PCa) is a widespread malignancy with global significance, which substantially affects cancer-related mortality. Its spectrum varies widely, from slow-progressing cases to aggressive or even lethal forms. Effective patient stratification into risk groups is crucial to therapeutic decisions and clinical trials. This review examines a wide range of diagnostic and prognostic biomarkers, several of which are integrated into clinical guidelines, such as the PHI, the 4K score, PCA3, Decipher, and Prolaris. It also explores the emergence of novel biomarkers supported by robust preclinical evidence, including urinary miRNAs and isoprostanes. Genetic alterations frequently identified in PCa, including BRCA1/BRCA2, ETS gene fusions, and AR changes, are also discussed, offering insights into risk assessment and precision treatment strategies. By evaluating the latest developments and applications of PCa biomarkers, this review contributes to an enhanced understanding of their role in disease management.
Funder
National Natural Science Foundation of China Natural Science Foundation of Beijing Municipality National High-Level Hospital Clinical Research Funding Peking University First Hospital Seed Foundation
Subject
Clinical Biochemistry
Reference115 articles.
1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries;Sung;CA Cancer J. Clin.,2021 2. (2022, December 01). Surveillance, Epidemiology, and End Results, Available online: https://seer.cancer.gov/. 3. High-risk prostate cancer-classification and therapy;Chang;Nat. Rev. Clin. Oncol.,2014 4. Radical prostatectomy versus observation for localized prostate cancer;Wilt;N. Engl. J. Med.,2012 5. Schaeffer, E.M., Srinivas, S., An, Y., Barocas, D., Bitting, R., Bryce, A., Chapin, B., Cheng, H.H., D’Amico, A.V., and Desai, N. (2022). Prostate Cancer, Available online: https://www.nccn.org/guidelines/.
|
|